Cantargia

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of the investor: Rockwood Strategic

Metlen Energy & Metals — Edison report on Metlen’s capital markets day: Made of metal, full of energy?

Inside the mind of the investor: Baillie Gifford’s Investment Trust Conference

Audiovisual

Latest

Regional REIT – executive interview

Avino Silver & Gold Mines – equity proposition

JPMorgan European Discovery Trust — Sharesoc webinar – JPMorgan European Discovery Trust

About Edison

About Edison

Careers

Cantargia (OMX: CANTA)

Latest Insights

Cantargia (OMX: CANTA) – Nadunolimab receives FDA Fast Track designation

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Cantargia (OMX: CANTA) breast cancer study fully recruited

Cantargia (OMX: CANTA) reports positive CAN10 update

Sector

Equity Analyst

Key Management

Research

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — Strong momentum in first nine months of FY22

Cantargia — New data support differentiation of nadunolimab

Cantargia — Recruitment milestone achieved

Cantargia — First patient treated under CIRIFOUR trial

Cantargia — A positive H122 supports clinical activity

Cantargia – executive interview

Cantargia — Announcement of rights issue

Cantargia — ASCO data do not disappoint

Thematics

Healthcare-focused trusts: A sector on the mend

Outlook for 2024: Life sciences – where has the conviction gone?

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

Subscribe to Edison